KALA BIO, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on December 30, 2025, with a report date of January 6, 2026. KALA BIO, Inc. (Nasdaq: KALA) entered into multiple material definitive agreements to resolve outstanding claims and payment obligations through the issuance of unregistered common stock.
Key Financial Metrics and Transactions
The filing details non-cash settlements and equity issuances rather than standard operating financial metrics. Key transactional values include:
- Total Equity Issued: 4,600,000 shares of Common Stock issued in private, unregistered transactions.
- Debt/Claim Resolution: Settlement of a $600,000 consulting obligation with Delaware IR LLC via stock issuance.
- Cash Outflow: A separate $2 million payment to Oxford Finance, LLC was disclosed in a related press release (January 5, 2026), though the specific terms of this payment are not detailed in this 8-K text.
- Liquidity Impact: The filing does not provide current cash balances, total debt, or liquidity ratios.
Material Changes and Settlements
The Company resolved three distinct obligations through the issuance of shares:
- Baker Bros. Advisors LP: Issued 900,000 shares to resolve claims regarding participation rights under prior financing. Included a six-month voting agreement granting the Company an irrevocable proxy for these shares.
- LifeSci Capital LLC: Issued 2,200,000 shares to settle payment obligations for financial advisory services.
- Delaware IR LLC: Issued 1,100,000 shares to settle an outstanding $600,000 balance for marketing and advertising services. This settlement includes a make-whole mechanism tied to future net sale proceeds of the shares.
- Employee Issuance: An additional 400,000 shares were issued to employees.
Outlook, Risks, and Contingencies
Management Commentary: The Company utilized Section 4(a)(2) exemptions for the unregistered sales of equity. The Delaware IR settlement introduces a contingent liability (make-whole provision) dependent on future stock sales.
Risks: The issuance of 4.6 million shares represents a significant dilution event for existing shareholders. The voting agreement with Baker Bros. temporarily consolidates voting control with the Board for six months.
Unusual Items: The filing references a $2 million cash payment to Oxford Finance, LLC made on or around January 2, 2026, which is noted as a separate event from the stock settlements but disclosed in the same regulatory window.
Investor Verification Checklist
- Verify the exact dilution impact of the 4,600,000 new shares on the current fully diluted share count.
- Review the full text of the Delaware IR Settlement (Exhibit 10.4) to understand the specific triggers and calculations for the make-whole provision.
- Confirm the Company's remaining cash position following the $2 million payment to Oxford Finance, LLC.
- Assess the status of the Baker Bros. voting agreement and its expiration timeline (six months from Dec 30, 2025).
- Check for any subsequent filings regarding the registration rights or resale restrictions on the newly issued shares.